Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.

Expert opinion on drug metabolism & toxicology - 1 Dec 2013

Espirito Santo Ana, Medeiros Rui

Abstract excerpt

INTRODUCTION: Chemotherapy is the current standard treatment for hematological malignancies for both curative and palliative purposes. Unfortunately, in the current treatment scenario chemotherapy resistance is an issue that is know to lead to a relapse in cancer. The multidrug resistance 1 (MDR1) gene is often involved in drug resistance and, so far, the best studied mechanism of resistance relates to the level...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Drug Resistance, Neoplasm

Share to Gene Expression Regulation, Neoplastic

Share to Lymphoma, Non-Hodgkin

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 24053936
DOI: 10.1517/17425255.2013.835803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.PMID 24053936Read ↗

Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.Semantic proximity Read ↗

Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma.Semantic proximity Read ↗

Drug Resistance in Non-Hodgkin LymphomasSemantic proximity Read ↗

Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.Semantic proximity Read ↗

Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosisSemantic proximity Read ↗

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistanceSemantic proximity Read ↗

MDR1 in immunity: friend or foe?Semantic proximity Read ↗

[MDR1 (ABCB1) gene encoding glycoprotein P (P-gp), a member of ABC transporter superfamily: consequences for therapy and progression of neoplastic diseases].Semantic proximity Read ↗

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).Semantic proximity Read ↗

Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.Semantic proximity Read ↗

Pharmacogenomics influence on MDR1-associated cancer resistance and innovative drug delivery approaches: advancing precision oncologySemantic proximity Read ↗

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.